PubMed

Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K.

Ward AJ, Salas M, Caro JJ, Owens D.

Cost Eff Resour Alloc. 2004 Apr 15;2(1):2.PMID: 15086954 [PubMed - as supplied by publisher]Related articlesFree article

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.

Salas M, Ward A, Caro J.

Clin Ther. 2002 Oct;24(10):1690-705.PMID: 12462297 [PubMed - indexed for MEDLINE]Related articles

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.PMID: 15099124 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55.PMID: 18435673 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Beale S, Bagust A, Shearer AT, Martin A, Hulme L.

Pharmacoeconomics. 2006;24 Suppl 1:21-34. Review.PMID: 16800160 [PubMed - indexed for MEDLINE]Related articles

Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.

Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA.

Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51.PMID: 15324515 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.

Brändle M, Azoulay M, Greiner RA.

Int J Clin Pharmacol Ther. 2007 Apr;45(4):203-20.PMID: 17474539 [PubMed - indexed for MEDLINE]Related articles

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.PMID: 16545208 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.PMID: 15669880 [PubMed - indexed for MEDLINE]Related articles

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237. PMID: 17192117 [PubMed - indexed for MEDLINE]Related articles

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.PMID: 18462574 [PubMed - indexed for MEDLINE]Related articlesFree article

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.PMID: 16800162 [PubMed - indexed for MEDLINE]Related articles

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L.

Pharmacoeconomics. 2007;25(3):253-66.PMID: 17335310 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.

Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU.

Curr Med Res Opin. 2004 Nov;20(11):1729-46.PMID: 15537473 [PubMed - indexed for MEDLINE]Related articles

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.

Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.

Curr Med Res Opin. 2005 Dec;21(12):2063-71.PMID: 16368057 [PubMed - indexed for MEDLINE]Related articles

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.PMID: 15147610 [PubMed - indexed for MEDLINE]Related articlesFree article

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.PMID: 19640359 [PubMed - indexed for MEDLINE]Related articles

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.PMID: 17593245 [PubMed - indexed for MEDLINE]Related articles

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.PMID: 17346499 [PubMed - indexed for MEDLINE]Related articlesFree article

Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States.

Caro JJ, Salas M, O'Brien JA, Ishak K, Sung J, Raggio G.

Value Health. 2004 Jan-Feb;7(1):13-21.PMID: 14720127 [PubMed - indexed for MEDLINE]Related articles